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Development of an effective vaccine against HIV has
posed significant challenges to the scientific community.
Lack of knowledge about the molecular pathogenesis of
this disease, and the absence of naturally occurring, pro-
tective immune responses, which is attributed in large part
to the diversity of the viral envelope and multiple escape
mechanisms, have made it difficult to design successful
candidates. Recent studies of the envelope have suggested
that it is possible to enhance immunogenicity of the enve-
lope by improving the breadth of the neutralizing anti-
body response and by stimulating cell-mediated
immunity. This relies on an understanding of the struc-
ture of HIV Env and the use of site-specific mutation to
create novel immunogens. Based on structural and func-
tional data, our lab has developed DNA and adenoviral
vectors which express envelope proteins containing alter-
ations to regions in the variable loop to better control tro-
pism and improve immunogenicity. These modified HIV
genetic vaccine candidates have been tested in combina-
tion with Gag, Pol, and Nef immunogens, and shown to
improve the potency of cellular and humoral immune
responses in primates. An initial Phase I trial (VRC 004)
dose escalation study to test a DNA vaccine composed of
a 4-plasmid combination of clade B gag/pol/nef with
clades A, B, and C envelope was recently completed in 50
healthy adults in the U.S. CD4+ and CD8+ T cell
responses were detected in the majority of vaccinees using
IFN-(ELISpot) and flow cytometric detection of intracellu-
lar IL-2 or IFN-γ. HIV-specific antibody response was
detected in about one third of vaccinees. Combination
modality regimens using a DNA vaccine prime followed
by a viral vector boost have shown promise in non-
human primate models of HIV infection. Phase I clinical
trials to test the safety and immunogenicity of an adeno-
viral vaccine expressing proteins similar to the DNA, and
a DNA prime, adenoviral boost regimen are in progress.
The initial adenoviral vector vaccine uses an Ad5 serotype
vector. However, pre-existing immunity can mitigate the
efficacy, so alternate serotypes and modifications to the
adenoviral fiber regions are being explored.
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